GPCR Therapeutics Demonstrates Clinical Improvement in Mobilization of Hematopoietic Stem Cells Using GPC-100/Burixafor in Clinical Pharmacology in Drug Development

GPCR Therapeutics, Inc., a clinical stage, international biopharmaceutical company with an innovative approach to drug discovery based on targeting G Protein Coupled Receptors (GPCR) pairs, announced today publication of their paper in Clinical Pharmacology in Drug Development (1), in collaboration with Taiwan’s ...

Related Keywords

United States ,Seoul ,Soult Ukpyolsi ,South Korea ,California ,Redwood City , ,Therapeutics Inc ,Taiwan Taigen Biotechnology Co ,Clinical Pharmacology In Drug Development ,Clinical Pharmacology ,Drug Development ,Taigen Biotechnology ,Burixafor Hydrobromide ,Novelc Xc Chemokine Receptor ,Progenitor Cells ,Healthy Subjects ,Dong Seung Seen ,Nature Scientific Reports ,